| Acne |
No |
| Active Half-Life |
4-6 hours |
| Active substance |
Stenabolic |
| Also known as |
SR9009, Stenabolic |
| Aromatization |
No |
| Blood pressure |
No significant impact reported |
| Chemical name |
Ethyl 3-[[(4-chlorobenzyl)((5-nitrothiophen-2-yl)methyl)amino]methyl]pyrrolidine-1-carboxylate |
| Classification |
PPAR alpha modifier |
| Dosage |
20-30 mg/day |
| Dosage (medical) |
Not clinically approved for medical use |
| Dosage (sports) |
Typically 10-40 mg per day |
| Effects |
Increased endurance, reduced fat mass, increased wakefulness |
| Formula |
C20H24ClN3O4S |
| Half-life |
Approximately 4-5 hours |
| HBR |
No |
| Hepatotoxicity |
No |
| Lab Test |
Specific tests for detection in blood or urine not widely detailed |
| Main action |
Activates Rev-ErbA which increases mitochondrial count in muscle, decreases fat storage |
| Side effects |
Potential alterations in circadian rhythms, limited data on long-term effects |
| Storage conditions |
Store at room temperature, away from moisture and light |
| Substance class |
Synthetic drug, Rev-ErbA ligand |
| Trade name |
Not available under any trade name as it is not commercially marketed |
| Use in sports |
Used as a performance-enhancing drug, not approved by WADA |
| WAREHOUSE |
International Warehouse 3 |
| Water Retention |
No |
| Manufacturer |
Ultima Pharmaceuticals |
